Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, Washington, United States of America.
School of Pharmacy, Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, United States of America.
PLoS One. 2018 Nov 1;13(11):e0206705. doi: 10.1371/journal.pone.0206705. eCollection 2018.
Antihypertensive treatments have been shown to reduce the risk of Alzheimer's disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer differential and additional protective benefits against AD compared with other AHTs, in addition to hypertension management.
In a retrospective cohort design, we examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis for 1,343,334 users of six different AHT drug treatments, 65 years of age or older (4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted for age, socioeconomic status, underlying health, and comorbidities.
RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting AHTs for males, (male OR = 0.931 (CI: 0.895-0.969)), but not so for females (female OR = 0.985 (CI: 0.963-1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both men (male ARB OR = 0.834 (CI: 0.788-0.884); male ACEI OR = 0.978 (CI: 0.939-1.019)) and women (female ARB OR = 0.941 (CI: 0.913-0.969); female ACEI OR = 1.022 (CI: 0.997-1.048)), but only in white men and white and black women. No association was shown for Hispanic men and women.
Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.
抗高血压治疗已被证明可降低阿尔茨海默病(AD)的风险。肾素-血管紧张素系统(RAS)与 AD 有关,因此与其他抗高血压药物相比,RAS 作用的抗高血压药物(血管紧张素转换酶抑制剂(ACEI)和血管紧张素 II 受体阻滞剂(ARB))可能对 AD 具有差异和额外的保护作用,除了高血压管理。
在回顾性队列设计中,我们检查了 2007 年至 2013 年 20%的 Medicare 受益人的医疗和药房索赔,并比较了 6 种不同抗高血压药物治疗的 1,343,334 名 65 岁及以上患者(4,215,338 人年)的 AD 诊断率。我们比较了 RAS 和非 RAS 抗高血压药物使用者之间以及 ACEI 和 ARB 使用者之间的 AD 风险,按性别和种族/民族进行比较。模型调整了年龄、社会经济地位、潜在健康状况和合并症。
RAS 作用的抗高血压药物对男性 AD 的发病有轻微的保护作用,而非 RAS 作用的抗高血压药物(男性 OR = 0.931(CI:0.895-0.969)),但对女性则不然(女性 OR = 0.985(CI:0.963-1.007))。与其他抗高血压药物相比,ARB 对男性(男性 ARB OR = 0.834(CI:0.788-0.884);男性 ACEI OR = 0.978(CI:0.939-1.019))和女性(女性 ARB OR = 0.941(CI:0.913-0.969);女性 ACEI OR = 1.022(CI:0.997-1.048))均优于 ACEI,而仅在白人男性和白人和黑人女性中如此。没有显示出西班牙裔男性和女性之间存在关联。
除了降低血压外,高血压管理治疗包括 RAS 作用的 ARB 可能会降低 AD 风险,尤其是对白人、黑人女性和白人男性。需要对来自不同种族和族裔群体的男性和女性进行更多的研究和临床试验,以证实这些发现。了解某些 RAS 作用的抗高血压药物在高危人群中的潜在有益作用非常重要。